Monday, October 29 2007
Includes the plenary sessions and scientific highlights from the head and neck, pancreatic, and lung cancer sessions as well as patient friendly summaries of key presentations.
A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity A Small Molecular Inhibitor of TGFß Protects Against the Development of Radiation Induced Lung Injury Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients wtih Complete Response to Definitive Chemoradiotherapy? Characterization of Pancreatic Tumor Motion Using 4D MRI: Surrogates for Tumor Position Should be Used With Caution Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) Post-resectional CA 19-9 Values >90 are Associated With Significantly Worse Survival in Patients With Pancreatic Carcinoma Treated With Adjuvant Therapy on RTOG 9704 - Implications for Current and Future Trials Prophylactic Cranial Irradiation (PCI) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EORTC 22993-08993) The Impact of Boost Dose and Margins on the Local Recurrence Rate in Breast Conserving Therapy: Results From the EORTC Boost-No Boost Trial The Integrin-TGFbeta Axis: Inhibition of Integrin Alpha v Beta6 Prevents Radiation-Induced Lung Fibrosis. Which Lung Volumes to Use for Radiotherapy Planning of Lung Cancer: Inspiration, Expiration, Averaged, or Free-breathing?